secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001193125-25-317541
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA
-------------------------------------------------------------------------------

- GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
- Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.
- IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.
- Cash runway guidance into 2030 remains unchanged despite the termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/0001193125-25-317541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/d800445d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-317541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer